🔗 Share this article The United States and United Kingdom Agree to Duty-Free Agreement on Prescription Drugs. Representative image of medicine trade. The UK and US have announced a significant bilateral deal that will maintain zero import taxes on UK drug shipments being sold in the American market. Agreement Details of the Pact As part of the deal, the UK has committed to increase spending on drugs through the National Health Service (NHS). This move guarantees that import taxes on these vital exports will remain at nothing for a duration of three years. This development follows earlier warnings to hike tariffs on patented pharmaceutical products, with figures discussed up to 100%. "This agreement between the UK reinforces the worldwide climate for cutting-edge drugs and establishes much-needed balance to American-British medicine commerce," a release noted. Trade Impact Pharmaceuticals are one of the the United Kingdom's most significant goods shipped to the America, which is by far the primary market for large companies like GSK and AstraZeneca. Statistics show that in the one-year period to the end of September, the UK shipped drugs valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of British export trade in that span. "This guarantee safeguards work, stimulates capital expenditure and facilitates the UK to emerge as a worldwide center for medical research," a minister commented. Specific NHS Changes The deal includes several specific commitments from the United Kingdom: Price Threshold Increase: The UK will increase the affordability limit at which it judges new medicines to be prohibitively costly by 25%. Increased NHS Spending: There is a target to raise overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years. Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at 15%. In the past, rebates exceeded 20%. Broader Context The pact follows a ongoing tension between the sector and the British authorities over medicine costs and regulatory access. These tensions were heightened by arguments that US consumers were paying significantly more for the identical medicines than consumers in the Britain and the EU. Recently, several significant manufacturing plans in the UK have been halted or abandoned, while major expansions have been pledged toward projects in the United States. The Science Minister stated that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the last ten years.
Representative image of medicine trade. The UK and US have announced a significant bilateral deal that will maintain zero import taxes on UK drug shipments being sold in the American market. Agreement Details of the Pact As part of the deal, the UK has committed to increase spending on drugs through the National Health Service (NHS). This move guarantees that import taxes on these vital exports will remain at nothing for a duration of three years. This development follows earlier warnings to hike tariffs on patented pharmaceutical products, with figures discussed up to 100%. "This agreement between the UK reinforces the worldwide climate for cutting-edge drugs and establishes much-needed balance to American-British medicine commerce," a release noted. Trade Impact Pharmaceuticals are one of the the United Kingdom's most significant goods shipped to the America, which is by far the primary market for large companies like GSK and AstraZeneca. Statistics show that in the one-year period to the end of September, the UK shipped drugs valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of British export trade in that span. "This guarantee safeguards work, stimulates capital expenditure and facilitates the UK to emerge as a worldwide center for medical research," a minister commented. Specific NHS Changes The deal includes several specific commitments from the United Kingdom: Price Threshold Increase: The UK will increase the affordability limit at which it judges new medicines to be prohibitively costly by 25%. Increased NHS Spending: There is a target to raise overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years. Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at 15%. In the past, rebates exceeded 20%. Broader Context The pact follows a ongoing tension between the sector and the British authorities over medicine costs and regulatory access. These tensions were heightened by arguments that US consumers were paying significantly more for the identical medicines than consumers in the Britain and the EU. Recently, several significant manufacturing plans in the UK have been halted or abandoned, while major expansions have been pledged toward projects in the United States. The Science Minister stated that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the last ten years.